Hansoh Pharmaceutical Group

Hansoh Pharmaceutical Group is a pharmaceutical company in China whose business focuses on major disease therapeutic areas such as oncology, metabolism, immunology, central nervous system diseases and anti-infectives. Its product portfolio includes Ameile (aumolertinib mesylate tablets), Hansoh Xinfu (flumatinib mesylate tablets), Pulaile (pemetrexed disodium for injection), Xintai (bortezomib for injection), Xinwei (imatinib mesylate tablets) and Tanneng (fosaprepitant dimeglumine for injection).

The company has established four R&D centers in Shanghai, Lianyungang, Changzhou, and Maryland (USA), and its R&D capabilities cover antibody-drug conjugates, synthetic peptides, siRNA, bispecific antibodies, and small molecules. To date, it has entered into out-licensing collaborations with pharmaceutical enterprises such as GSK, MSD, Regeneron and Roche.